Scholars Central

OtherPublished 21 Jul 2016

Strategies to overcome endocrine therapy resistance in hormone receptor-positive advanced breast cancer

Authors: Rowan T Chlebowski

Clinical Investigation

Volume 4 · Issue 1 · Pages 19–33

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Use of endocrine therapies has made hormone receptor-positive breast cancer a manageable disease if diagnosed at an early stage. However, endocrine therapy resistance is a persistent problem in patients with advanced breast cancer. Ongoing research has identified a number of mechanisms that may mediate resistance, including estrogenindependent activation of the estrogen receptor; increased signaling through the RAS/MAPK, NF-kB, or PI3K/Akt/mTOR pathway; and maintenance of cyclin D1 expression. Based on such findings, various strategies to overcome endocrine resistance have been developed. Although some therapies are in early development, others are available in the clinic. The novel treatment strategies under evaluation in clinical trials for managing patients with endocrine-resistant advanced breast cancer will be reviewed in combination with endocrine therapy.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Clinical Investigation.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalClinical Investigation
  • SubjectGeneral & Internal Medicine
  • BylineArticles whose byline prints “Rowan T Chlebowski”